Estudo randomizado | Efeito do canrelizumabe vs. placebo adicionado à quimioterapia na sobrevida e na sobrevida livre de progressão em pacientes com carcinoma esofágico de células escamosas avançado ou metastático.
17 Set, 2021 | 11:55hEffect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Editorial: Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma—Renewed Enthusiasm and a Lingering Challenge – JAMA Oncology (gratuito por tempo limitado)
Comentário no Twitter
Among patients with advanced or metastatic esophageal squamous cell carcinoma, the addition of camrelizumab to chemotherapy, compared with placebo and chemotherapy, significantly improved overall survival and progression-free survival https://t.co/DAlhmtgvv1
— JAMA (@JAMA_current) September 14, 2021